Press Releases
Date picker
Category
Results per page
Kancera announces the discovery of a new class of compounds against cancer
Kancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe…
Interim Report for Kancera AB (publ) Q3 2013
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…
Interim Report for Kancera AB (publ) Q2 2013
Regulatory
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there…
Kancera is awarded € 950,000 for the development of drugs to treat severe parasitic diseases
Kancera together with international research groups in the project A-PARADDISE has been awarded a grant from the European Union Seventh Framework Programme to develop drugs to combat severe parasitic diseases…
Kancera; Update regarding the ROR project
Kancera reports progress in the development of a ROR-inhibiting cancer drug. The compound KAN0439365 is effective against cancer cells from patients and show good metabolic stability in human liver cells…
Interim Report for Kancera AB (publ) Q1 2013
Regulatory
January 1 - March 31, 2013 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB. Therefore…
Full Year Report 2012 for Kancera AB (publ) January 1 – December 31, 2012
Regulatory
All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill…
Interim Report for Kancera AB (publ) Q3 2012
Regulatory
All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill…
Kancera strengthens the evidence that pancreatic cancer is dependent on ROR
Kancera reports results from a collaboration with Professor Håkan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer…
Kancera reports inhibitory effects on pancreatic cancer in animal studies
Kancera reports that the company's first generation of PFKFB3 inhibiting compounds reduces growth of pancreatic cancer in a pre-clinical animal study.